Barcelona-based BASE4 Biosciences has closed a $1 million pre-seed round to develop a multi-omic platform that infers the biological state and age of 47 tissues from a single blood sample – using sex-specific models designed to capture the biological variability that clinical research has historically excluded.
The round was backed by Baobab Ventures, Kfund, Itnig, Masia, and angel investors.
The platform combines transcriptomics, genomics, and AI to analyze over 15,000 genes and 330 metabolic pathways, translating molecular signals into organ-level health insights across nine functional areas including hormonal health, reproductive health (ovarian, vaginal, and uterine), cardiovascular, cognitive, and mammary health. The company says it can detect transcriptomic alterations linked to functional decline before symptoms appear or conventional diagnostics show abnormalities.
The women’s health angle is central to the thesis, not adjacent. BASE4 points to the well-documented exclusion of women from clinical trials until the 1990s as a foundational gap – their biological variability was treated as noise rather than signal. The consequences persist: women are diagnosed later than men across hundreds of diseases, ovarian tissue ages roughly five times faster than other body tissues, and over 75% of IVF cycles still fail in women over 35.
BASE4 is launching with three clinical programs: fertility and women’s health (focused on ovarian biology and menopause-related changes), preventive health (detecting early molecular signs of tissue dysfunction), and pharma/clinical research (pharmacotranscriptomics for earlier detection of treatment toxicity at the tissue level).
The company is supported by over €7 million in total research funding and is led by molecular biologist Dr. Jose Manuel Soria, with a clinical team that includes gynecologists specializing in reproductive medicine and functional medicine. BASE4 has operations in Barcelona and Riyadh.
